Trials / Completed
CompletedNCT00408785
A Study Of BOTOX For The Treatment Of Glabellar Lines
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of BOTOX? (Botulinum Toxin Type A) in Subjects With Glabellar Lines
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 256 (planned)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a Multicenter, double-blind, randomized, placebo-controlled, parallel-group comparative study to confirm the efficacy and safety of BOTOX 20 units single injection for the Chinese patients with glabellar lines. The subjects will receive a single intramuscular treatment consisting of 5 injections of either BOTOX? 20U or placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Botulinum Toxin Type A | botulinum toxin type A 100 units, human serum albumin 0.5 mg, sodium chloride 0.9 mg |
| DRUG | sodium chloride | sodium chloride 0.9 mg |
Timeline
- Start date
- 2006-11-01
- Primary completion
- 2007-05-09
- Completion
- 2007-05-09
- First posted
- 2006-12-07
- Last updated
- 2017-05-31
Locations
4 sites across 1 country: China
Source: ClinicalTrials.gov record NCT00408785. Inclusion in this directory is not an endorsement.